Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Activity of antibiotics against Staphylococcus aureus in an in vitro model of biofilms in the context of cystic fibrosis: influence of the culture medium.

Diaz Iglesias Y, Wilms T, Vanbever R, Van Bambeke F.

Antimicrob Agents Chemother. 2019 Apr 29. pii: AAC.00602-19. doi: 10.1128/AAC.00602-19. [Epub ahead of print]

PMID:
31036685
2.

Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.

Tulkens PM, Van Bambeke F, Zinner SH.

Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S213-S222. doi: 10.1093/cid/ciy1079.

3.

Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock.

Ngougni Pokem P, Capron A, Wallemacq P, Tulkens PM, Van Bambeke F, Laterre PF.

J Antimicrob Chemother. 2019 Jan 14. doi: 10.1093/jac/dky565. [Epub ahead of print] No abstract available.

PMID:
30649374
4.

Investigation of unbound colistin A and B in clinical samples using a mass spectrometry method.

Fage D, Deprez G, Wolff F, Hites M, Jacobs F, Van Bambeke F, Cotton F.

Int J Antimicrob Agents. 2019 Mar;53(3):330-336. doi: 10.1016/j.ijantimicag.2018.10.017. Epub 2018 Nov 2.

PMID:
30391382
5.

1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.

Ameryckx A, Thabault L, Pochet L, Leimanis S, Poupaert JH, Wouters J, Joris B, Van Bambeke F, Frédérick R.

Eur J Med Chem. 2018 Nov 5;159:324-338. doi: 10.1016/j.ejmech.2018.09.067. Epub 2018 Sep 28.

PMID:
30300845
6.

Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient.

Lozano C, Azcona-Gutiérrez JM, Van Bambeke F, Sáenz Y.

PLoS One. 2018 Sep 13;13(9):e0204167. doi: 10.1371/journal.pone.0204167. eCollection 2018.

7.

Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.

Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2018 Nov;52(5):697-701. doi: 10.1016/j.ijantimicag.2018.07.027. Epub 2018 Aug 3.

PMID:
30081137
8.

The Putative De-N-acetylase DnpA Contributes to Intracellular and Biofilm-Associated Persistence of Pseudomonas aeruginosa Exposed to Fluoroquinolones.

Khandekar S, Liebens V, Fauvart M, Tulkens PM, Michiels J, Van Bambeke F.

Front Microbiol. 2018 Jul 10;9:1455. doi: 10.3389/fmicb.2018.01455. eCollection 2018.

9.

Anidulafungin increases the antibacterial activity of tigecycline in polymicrobial Candida albicans/Staphylococcus aureus biofilms on intraperitoneally implanted foreign bodies.

Rogiers O, Holtappels M, Siala W, Lamkanfi M, Van Bambeke F, Lagrou K, Van Dijck P, Kucharíková S.

J Antimicrob Chemother. 2018 Oct 1;73(10):2806-2814. doi: 10.1093/jac/dky246.

PMID:
30010876
10.

Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models.

Siala W, Rodriguez-Villalobos H, Fernandes P, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00598-18. doi: 10.1128/AAC.00598-18. Print 2018 Jul.

11.

Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.

Miranda Bastos AC, Vandecasteele SJ, Spinewine A, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2018 Jun 1;73(6):1630-1638. doi: 10.1093/jac/dky078.

PMID:
29579214
12.

Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.

Peyrusson F, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02245-17. doi: 10.1128/AAC.02245-17. Print 2018 Apr.

13.

Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?

Coenye T, Goeres D, Van Bambeke F, Bjarnsholt T.

Clin Microbiol Infect. 2018 Jun;24(6):570-572. doi: 10.1016/j.cmi.2018.01.003. Epub 2018 Jan 11. No abstract available.

14.

Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models.

Defraine V, Verstraete L, Van Bambeke F, Anantharajah A, Townsend EM, Ramage G, Corbau R, Marchand A, Chaltin P, Fauvart M, Michiels J.

Front Microbiol. 2017 Dec 22;8:2585. doi: 10.3389/fmicb.2017.02585. eCollection 2017.

15.

Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism, and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically Relevant Concentrations in Cultured Human HL-60 Promyelocytes and THP-1 Monocytes.

Milosevic TV, Payen VL, Sonveaux P, Muccioli GG, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01599-17. doi: 10.1128/AAC.01599-17. Print 2018 Mar.

16.

Synergy between Ursolic and Oleanolic Acids from Vitellaria paradoxa Leaf Extract and β-Lactams against Methicillin-Resistant Staphylococcus aureus: In Vitro and In Vivo Activity and Underlying Mechanisms.

Catteau L, Reichmann NT, Olson J, Pinho MG, Nizet V, Van Bambeke F, Quetin-Leclercq J.

Molecules. 2017 Dec 16;22(12). pii: E2245. doi: 10.3390/molecules22122245.

17.

Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

Delattre IK, Taccone FS, Jacobs F, Hites M, Dugernier T, Spapen H, Laterre PF, Wallemacq PE, Van Bambeke F, Tulkens PM.

Expert Rev Anti Infect Ther. 2017 Jul;15(7):677-688. doi: 10.1080/14787210.2017.1338139. Epub 2017 Jun 19.

PMID:
28571493
18.

Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients.

Mustafa MH, Khandekar S, Tunney MM, Elborn JS, Kahl BC, Denis O, Plésiat P, Traore H, Tulkens PM, Vanderbist F, Van Bambeke F.

Eur Respir J. 2017 May 19;49(5). pii: 1601847. doi: 10.1183/13993003.01847-2016. Print 2017 May.

19.

Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms.

Anantharajah A, Buyck JM, Sundin C, Tulkens PM, Mingeot-Leclercq MP, Van Bambeke F.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02566-16. doi: 10.1128/AAC.02566-16. Print 2017 Jun.

20.

Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.

Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, Van Bambeke F, Sánchez-Díaz AM, Zamorano L, Oliver A, Cantón R.

J Antimicrob Chemother. 2017 May 1;72(5):1421-1428. doi: 10.1093/jac/dkx001.

PMID:
28158470
21.

Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa.

Buyck JM, Luyckx C, Muccioli GG, Krause KM, Nichols WW, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2017 May 1;72(5):1400-1409. doi: 10.1093/jac/dkw587.

PMID:
28137941
22.

High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations.

Chalhoub H, Sáenz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2016 Dec;48(6):740-743. doi: 10.1016/j.ijantimicag.2016.09.012. Epub 2016 Oct 19.

PMID:
28128097
23.

Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic.

Chalhoub H, Pletzer D, Weingart H, Braun Y, Tunney MM, Elborn JS, Rodriguez-Villalobos H, Plésiat P, Kahl BC, Denis O, Winterhalter M, Tulkens PM, Van Bambeke F.

Sci Rep. 2017 Jan 16;7:40208. doi: 10.1038/srep40208.

24.

The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase.

Siala W, Kucharíková S, Braem A, Vleugels J, Tulkens PM, Mingeot-Leclercq MP, Van Dijck P, Van Bambeke F.

Nat Commun. 2016 Nov 3;7:13286. doi: 10.1038/ncomms13286.

25.

Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Mustafa MH, Chalhoub H, Denis O, Deplano A, Vergison A, Rodriguez-Villalobos H, Tunney MM, Elborn JS, Kahl BC, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6735-6741. doi: 10.1128/AAC.01046-16. Print 2016 Nov.

26.

Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs Pseudomonas aeruginosa Pathogenicity and Inflammasome Activation.

Anantharajah A, Faure E, Buyck JM, Sundin C, Lindmark T, Mecsas J, Yahr TL, Tulkens PM, Mingeot-Leclercq MP, Guery B, Van Bambeke F.

J Infect Dis. 2016 Oct 1;214(7):1105-16. doi: 10.1093/infdis/jiw295. Epub 2016 Jul 13.

PMID:
27412581
27.

Targeting the Type Three Secretion System in Pseudomonas aeruginosa.

Anantharajah A, Mingeot-Leclercq MP, Van Bambeke F.

Trends Pharmacol Sci. 2016 Sep;37(9):734-749. doi: 10.1016/j.tips.2016.05.011. Epub 2016 Jun 22. Review.

PMID:
27344210
28.

Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014).

Ceyssens PJ, Van Bambeke F, Mattheus W, Bertrand S, Fux F, Van Bossuyt E, Damée S, Nyssen HJ, De Craeye S, Verhaegen J; Belgian Streptococcus pneumoniae Study Group, Tulkens PM, Vanhoof R.

PLoS One. 2016 May 26;11(5):e0154816. doi: 10.1371/journal.pone.0154816. eCollection 2016.

29.

Synergistic activity between an antimicrobial polyacrylamide and daptomycin versus Staphylococcus aureus biofilm.

Siala W, Van Bambeke F, Taresco V, Piozzi A, Francolini I.

Pathog Dis. 2016 Jul;74(5). pii: ftw042. doi: 10.1093/femspd/ftw042. Epub 2016 May 5.

PMID:
27154750
30.

Modulating antibiotic activity towards respiratory bacterial pathogens by co-medications: a multi-target approach.

Vandevelde NM, Tulkens PM, Van Bambeke F.

Drug Discov Today. 2016 Jul;21(7):1114-29. doi: 10.1016/j.drudis.2016.04.001. Epub 2016 Apr 16. Review.

PMID:
27094105
31.

The role of solithromycin in the management of bacterial community-acquired pneumonia.

Van Bambeke F, Tulkens PM.

Expert Rev Anti Infect Ther. 2016;14(3):311-24. doi: 10.1586/14787210.2016.1138857. Epub 2016 Feb 5. Review.

PMID:
26848612
32.

Increase of efflux-mediated resistance in Pseudomonas aeruginosa during antibiotic treatment in patients suffering from nosocomial pneumonia.

Riou M, Avrain L, Carbonnelle S, El Garch F, Pirnay JP, De Vos D, Plésiat P, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2016 Jan;47(1):77-83. doi: 10.1016/j.ijantimicag.2015.11.004. Epub 2015 Nov 26.

PMID:
26691019
33.

ANALYSIS OF THE MODE OF ACTION OF A PSEUDOMONAS AERUGINOSA ANTI-PERSISTER COMPOUND.

Defrayne V, Liebens V, Swings T, Corbau R, Marchand A, Chaltin P, Van Bambeke F, Anantharajah A, Fauvart M, Michiels J.

Commun Agric Appl Biol Sci. 2015;80(1):137-43. No abstract available.

PMID:
26630768
34.

Editorial Commentary: Colistin and a New Paradigm in Drug Development.

Van Bambeke F, Tulkens PM.

Clin Infect Dis. 2016 Mar 1;62(5):559-60. doi: 10.1093/cid/civ968. Epub 2015 Nov 25. No abstract available.

PMID:
26607423
35.

Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Van Bambeke F.

Drugs. 2015 Dec;75(18):2073-95. doi: 10.1007/s40265-015-0505-8. Review.

PMID:
26603874
36.

Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients.

Vandecasteele SJ, Miranda Bastos AC, Capron A, Spinewine A, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2015 Dec;46(6):660-5. doi: 10.1016/j.ijantimicag.2015.09.005. Epub 2015 Oct 9.

PMID:
26603304
37.

In Vitro Models for the Study of the Intracellular Activity of Antibiotics.

Buyck JM, Lemaire S, Seral C, Anantharajah A, Peyrusson F, Tulkens PM, Van Bambeke F.

Methods Mol Biol. 2016;1333:147-57. doi: 10.1007/978-1-4939-2854-5_13.

PMID:
26468107
38.

Correlation between cytotoxicity induced by Pseudomonas aeruginosa clinical isolates from acute infections and IL-1β secretion in a model of human THP-1 monocytes.

Anantharajah A, Buyck JM, Faure E, Glupczynski Y, Rodriguez-Villalobos H, De Vos D, Pirnay JP, Bilocq F, Guery B, Tulkens PM, Mingeot-Leclercq MP, Van Bambeke F.

Pathog Dis. 2015 Oct;73(7). pii: ftv049. doi: 10.1093/femspd/ftv049. Epub 2015 Jul 22.

40.
41.

Reviving old antibiotics.

Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, Turnidge JD, Kahlmeter G.

J Antimicrob Chemother. 2015 Aug;70(8):2177-81. doi: 10.1093/jac/dkv157. Epub 2015 Jun 10. Review.

PMID:
26063727
42.
43.

Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum.

Ngougni Pokem P, Miranda Bastos AC, Tulkens PM, Wallemacq P, Van Bambeke F, Capron A.

Clin Biochem. 2015 May;48(7-8):542-5. doi: 10.1016/j.clinbiochem.2015.02.006. Epub 2015 Feb 21.

PMID:
25712752
44.

Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms.

Vandevelde NM, Tulkens PM, Muccioli GG, Van Bambeke F.

J Antimicrob Chemother. 2015;70(6):1713-26. doi: 10.1093/jac/dkv032. Epub 2015 Feb 23.

PMID:
25712316
45.

Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.

Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O, Plésiat P, Kahl BC, Van Bambeke F, Tulkens PM.

J Antimicrob Chemother. 2015 May;70(5):1596-8. doi: 10.1093/jac/dku551. Epub 2015 Jan 14. No abstract available.

PMID:
25587996
46.

Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Buyck JM, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2015 Jan;59(1):258-68. doi: 10.1128/AAC.04011-14. Epub 2014 Oct 27.

47.

Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.

Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, Van Bambeke F, Wallemacq P, Descy J, Lambermont B, Layios N, Damas P, Moutschen M.

J Antimicrob Chemother. 2015 Jan;70(1):207-16. doi: 10.1093/jac/dku354. Epub 2014 Sep 12.

PMID:
25216821
48.

Characterisation of a collection of Streptococcus pneumoniae isolates from patients suffering from acute exacerbations of chronic bronchitis: in vitro susceptibility to antibiotics and biofilm formation in relation to antibiotic efflux and serotypes/serogroups.

Vandevelde NM, Tulkens PM, Diaz Iglesias Y, Verhaegen J, Rodriguez-Villalobos H, Philippart I, Cadrobbi J, Coppens N, Boel A, Van Vaerenbergh K, Francart H, Vanhoof R, Liistro G, Jordens P, d'Odemont JP, Valcke Y, Verschuren F, Van Bambeke F.

Int J Antimicrob Agents. 2014 Sep;44(3):209-17. doi: 10.1016/j.ijantimicag.2014.05.016. Epub 2014 Jul 7.

PMID:
25123808
49.

Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates.

Siala W, Mingeot-Leclercq MP, Tulkens PM, Hallin M, Denis O, Van Bambeke F.

Antimicrob Agents Chemother. 2014 Nov;58(11):6385-97. doi: 10.1128/AAC.03482-14. Epub 2014 Aug 11.

50.

Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.

Van Bambeke F.

Ann Med. 2014 Nov;46(7):512-29. doi: 10.3109/07853890.2014.935470. Epub 2014 Jul 24. Review.

PMID:
25058176

Supplemental Content

Loading ...
Support Center